spacer
home > ict > spring 2006 > calling all innovators
PUBLICATIONS
International Clinical Trials

Calling all Innovators

Intelligent interpretation of regulations can breed confidence and bring innovation back to pharma, says Ian Leake of BearingPoint

The pharmaceutical industry is being challenged like never before. Increasing regulation, globalisation, and the neverending search for blockbusters have all contributed to spiralling costs. Yet greater public oversight of healthcare costs is making it harder for the industry to maintain its traditional profitability.

Industry executives have responded in several ways: consolidation (mergers and acquisitions), searching for lower cost locations (globalisation), and demands to make sweeping cuts to departmental budgets – in some cases as much as 30 per cent from year to year. But all of this activity requires flexibility and promotes change, and if there’s one thing that the industry has learnt over the years it’s that change invites risk. And this heavily regulated industry is extremely risk averse.

A major contributor to the risk averse culture in the industry is the traditional approach to regulatory compliance (socalled ‘old compliance’). Overlapping and sometimes conflicting global and local regulations, accepted and rarely challenged ‘best practices,’ and personal interpretations have created a complex and expensive web of policies and procedures that make change costly, painful, and tiresome. The biggest casualty of this has been innovation. In all areas of operation – from clinical trials to manufacturing to finance – it is just too hard to innovate: it’s easier and safer to just keep doing the same thing, even if it’s unsustainably slow and expensive.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Ian Leake is a Senior Manager in BearingPoint’s Global Life Sciences Practice, and has 14 years’ experience in the pharmaceutical industry. He has extensive expertise in leading R&D, regulatory compliance and systems integration projects and programmes. Ian currently leads BearingPoint’s Regulatory Compliance Team in the UK.
spacer
Ian Leake
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ICON named best Contract Research Organisation in latest string of awards and recognitions

ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, is proud to announce it was named the “Best Contract Research Organisation” of 2021 during the 17th Annual Scrip Awards ceremony on 2 December.
More info >>

White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement